GSK

Gsk PLC

Health Care First-pass screen £78.2bn

410/1000 Overall fit

AI beneficiary 35% 20

Operating leverage 25% 65

Valuation 25% 30

Downside protection 15% 70

First-pass take

Mature pharma with strong Specialty growth (Oncology +43%, HIV +11%) and robust FCF (£4bn, +41%), but minimal AI beneficiary exposure. Lacks valuation data and faces regulatory pricing headwinds, positioning it poorly for a strategy focused on AI spending exposure and operational leverage at attractive valuations.

Flags

no-valuation-dataregulatory-pressuremature-pharma